Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.95 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.44 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | TDO2 | P48775 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2459100 | 1.00 | ADRB2 (0.95) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL25383293 | 1.00 | ADRB2 (0.95) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| SCHEMBL138590 | 0.97 | ADRB2 (1.00) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| SCHEMBL140922 | 0.97 | ADRB2 (1.00) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| SCHEMBL177057 | 0.97 | ADRB2 (1.00) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| Bromide SCHEMBL28703130 | 0.95 | ADRB2 (0.95) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| Iodide SCHEMBL29127483 | 0.95 | ADRB2 (0.95) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| SCHEMBL10804179 | 0.90 | ADRB2 (0.86) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL27957365 | 0.87 | ADRB2 (0.72) | ADRB2IDO1TDO2SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL28673897 | 0.83 | ADRB2 (0.67) | ADRB2IDO1LMNAHTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165262-A1 | THIENO-NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693545-A | Thieno nitrogen-containing heterocyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 上海科技大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-116693536-A | Pyrrolotriazinone compound, pharmaceutical composition containing pyrrolotriazinone compound, preparation method and application of pyrrolotriazinone compound | 上海科技大学 | 2023-09-05 | — | — | CN | disclosed |
| CN-110078736-B | Pyrazolopyrimidine derivative, process for producing the same, and use thereof | 广州白云山医药集团股份有限公司白云山制药总厂 | 2021-08-03 | — | — | CN | disclosed |
| EP-3404736-A1 | PHOSPHORESCENT MATERIALS | Universal Display Corporation (US) | 2018-11-21 | — | — | EP | disclosed |
| US-10084143-B2 | Phosphorescent materials | UNIVERSAL DISPLAY CORPORATION (US) | 2018-09-25 | — | — | US | disclosed |
| EP-2999021-B1 | PHOSPHORESCENT MATERIALS | UNIVERSAL DISPLAY CORP (US) | 2018-08-08 | — | — | EP | disclosed |
| EP-2999021-A1 | PHOSPHORESCENT MATERIALS | Universal Display Corporation (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2329541-B1 | PHOSPHORESCENT MATERIALS | UNIVERSAL DISPLAY CORP (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20150255734-A1 | PHOSPHORESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2015-09-10 | — | — | US | disclosed |
| US-9034483-B2 | Phosphorescent materials | UNIVERSAL DISPLAY CORPORATION (US) | 2015-05-19 | — | — | US | disclosed |
| EP-2329541-A1 | PHOSPHORESCENT MATERIALS | Universal Display Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100090591-A1 | PHOSPHORESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010033550-A1 | PHOSPHORESCENT MATERIALS | UNIVERSAL DISPLAY CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-0618907-B1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | BRITISH TECH GROUP INT (GB) | 1999-04-28 | — | — | EP | disclosed |
| US-5547972-A | 1-(ARLALKYLAMINOALKYL) IMIDAZOLE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1996-08-20 | — | — | US | disclosed |
| WO-1993013075-A1 | 1-(ARYLALKYL-AMINOALKYL)IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARATION AND USE AS THERAPEUTICAL AGENTS | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150255734-A1 | PHOSPHORESCENT MATERIALS | PPA1, PHOSPHO1, PPP1CC | ADRB2 4837/4885SLC6A3 3195/4885SLC6A2 3230/4885 |
| US-20100090591-A1 | PHOSPHORESCENT MATERIALS | PPA1, PHOSPHO1, PPP1CC | ADRB2 4837/4885SLC6A3 3195/4885SLC6A2 3230/4885 |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | GPR139, GPR132, GPR142 | ADRB2 112/4885SLC6A3 2219/4885SLC6A2 2708/4885 |
| US-10084143-B2 | Phosphorescent materials | PPA1, MTAP, NES | ADRB2 4229/4885SLC6A3 1448/4885SLC6A2 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.